機構調研A股最熱排名 | 10月27日
上週五至本週二,滬深兩市約81家上市公司被機構調研。機構調研榜單中,共有40家公司獲20家以上機構扎堆調研。邁瑞醫療最受關注,參與調研的機構達到613家,其中包括Citi、銀杏環球資本、CPE源峯投資等公司。海康威視被373家機構調研,榜單中排名第二。

個股調研次數來看,廣汽集團機構調研最爲密集,共獲機構17次調研。盟升電子、鼎通科技等公司也有機構調研,分別被機構調研5次、3次。

行業機構調研來看,醫療設備板塊行業位居榜首,共接待857家機構,其中包括邁瑞醫療(613家)、楚天科技(162家)、魚躍醫療(82家)等3家公司。電子板塊、電氣設備板塊等行業位居二、三,分別被670家、355家機構調研。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.